Fig. 5
Clinical improvement with dual inhibition of IL-4Rα and IL-17 A is accompanied by reduction of immunopathogenic T cell populations. (A) Clinical and treatment course of the index patient. (B) TriMAP of all stimulated T cell immune populations in the index patient for all timepoints before and after treatment initiation. (C) TriMAP showing changes in stimulated T cell immune populations before and after treatment, stratified by time point. Differences in immune populations before and after treatment are colored gray. (D) TriMAP plot of the expression of each individual marker in stimulated T cells in the index patient. (E) Bar plot showing percentages of subtypes of stimulated CD3 + T cells in the index patient at different treatment time points. (F) Subpopulations of the percentage of stimulated CD3 + T cell types shown in e: γVδ T cells are stratified by γVδ1TCR and γVδ2TCR cells. CD4 T cells are stratified by naive CD4 (CD3 + CD4 + CD45RA+) and memory CD4 (CD3 + CD4 + CD45RO+) T cells. CD8 T cells are stratified by naive CD8 (CD3 + CD8 + CD45RA+) and memory CD8 (CD3 + CD4 + CD45RO+) T cells. (G) T-distributed stochastic neighbor embedding (tSNE) plot of all unstimulated T cells in the index patient in the three timepoints. (H) tSNE plots showing changes in unstimulated T cell immune populations before and after treatment, stratified by time point. Differences in immune populations before and after treatment are colored gray. (I) tSNE plots of the expression of each individual marker in unstimulated T cells in the index patient. T0, before treatment, T1 and T2, after treatment.
